Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
MylanN. V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally.
It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases.
In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts.
The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.
Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals.
MylanN. V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 20 | 1.31 Increased by +11.97% | 1.17 Increased by +11.97% |
| Aug 6, 20 | 1.11 Increased by +7.77% | 0.98 Increased by +13.27% |
| May 11, 20 | 0.90 Increased by +9.76% | 0.86 Increased by +4.65% |
| Feb 27, 20 | 1.40 Increased by +7.69% | 1.28 Increased by +9.37% |
| Nov 5, 19 | 1.17 Decreased by -6.40% | 1.13 Increased by +3.54% |
| Jul 29, 19 | 1.03 Decreased by -3.74% | 0.95 Increased by +8.42% |
| May 7, 19 | 0.82 Decreased by -14.58% | 0.79 Increased by +3.80% |
| Feb 26, 19 | 1.30 Decreased by -9.09% | 1.36 Decreased by -4.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 20 | 2.97 B Increased by +0.35% | 185.70 M Increased by +2.15% | Increased by +6.25% Increased by +1.79% |
| Jun 30, 20 | 2.73 B Decreased by -4.22% | 39.40 M Decreased by -38.72% | Increased by +1.44% Decreased by -36.03% |
| Mar 31, 20 | 2.62 B Increased by +4.96% | 20.80 M Increased by +110.20% | Increased by +0.79% Increased by +109.71% |
| Dec 31, 19 | 3.19 B Increased by +3.67% | 20.50 M Decreased by -90.28% | Increased by +0.64% Decreased by -90.63% |
| Sep 30, 19 | 2.96 B Increased by +3.47% | 181.80 M Decreased by -12.47% | Increased by +6.14% Decreased by -15.40% |
| Jun 30, 19 | 2.85 B Increased by +1.54% | 64.30 M Increased by +64.40 K% | Increased by +2.25% Increased by +63.43 K% |
| Mar 31, 19 | 2.50 B Decreased by -7.04% | -204.00 M Decreased by -208.62% | Decreased by -8.17% Decreased by -232.00% |
| Dec 31, 18 | 3.08 B Decreased by -4.95% | 211.00 M Decreased by -48.52% | Increased by +6.85% Decreased by -45.85% |